Malcolm J. Moore
Impact in
- Oncology top 0.01%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Research top 0.05%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 137
- Pancreatic and Hepatic Oncology Research 72
- Colorectal Cancer Treatments and Studies 35
- Cancer Treatment and Pharmacology 16
-
- Cancer Genomics and Diagnostics 31
- Co-authors
- Dongsheng Tu (19 shared papers)Mace L. Rothenberg (6 shared papers)Steven Gallinger (13 shared papers)Russell K. Portenoy (5 shared papers)Daniel D. Von Hoff (6 shared papers)John Sahl Andersen (3 shared papers)Anna Maria Storniolo (3 shared papers)M. Christine Cripps (3 shared papers)
- Journals
- Journal of Clinical Oncology (42 papers)Annals of Oncology (22 papers)Clinical Cancer Research (15 papers)Investigational New Drugs (14 papers)Nature Communications (12 papers)
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Malcolm J. Moore
314 papers receiving 55.9k citations
Malcolm J. Moore's Hit Papers
Peers
Comparison fields: 5 of 182
- Oncology 29.6k
- Cancer Research 11.8k
- Pulmonary and Respiratory Medicine 9.7k
- Hepatology 2.3k
- Pathology and Forensic Medicine 5.1k
Countries citing papers authored by Malcolm J. Moore
This map shows the geographic impact of Malcolm J. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm J. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm J. Moore more than expected).
Fields of papers citing papers by Malcolm J. Moore
This network shows the impact of papers produced by Malcolm J. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm J. Moore. The network helps show where Malcolm J. Moore may publish in the future.
Co-authors
The 25 scholars most cited alongside Malcolm J. Moore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 316 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine Hit paper breakdown → | 2013 | 5355 |
| 2 | Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Hit paper breakdown → | 1997 | 4973 |
| 3 | Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group Hit paper breakdown → | 2007 | 3124 |
| 4 | K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer Hit paper breakdown → | 2008 | 3052 |
| 5 | Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer Hit paper breakdown → | 2000 | 2540 |
| 6 | The repertoire of mutational signatures in human cancer Hit paper breakdown → | 2020 | 2339 |
| 7 | Pan-cancer analysis of whole genomes Hit paper breakdown → | 2020 | 2109 |
| 8 | Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study Hit paper breakdown → | 2000 | 1862 |
| 9 | Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer Hit paper breakdown → | 2003 | 1798 |
| 10 | Cetuximab for the Treatment of Colorectal Cancer Hit paper breakdown → | 2007 | 1542 |
| 11 | Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer Hit paper breakdown → | 2005 | 1495 |
| 12 | Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial Hit paper breakdown → | 2014 | 1411 |
| 13 | Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. Hit paper breakdown → | 1996 | 1277 |
| 14 | Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection Hit paper breakdown → | 2010 | 1105 |
| 15 | The evolutionary history of 2,658 cancers Hit paper breakdown → | 2020 | 705 |
| 16 | Advanced pancreatic carcinoma: current treatment and future challenges Hit paper breakdown → | 2010 | 679 |
| 17 | 2009 | 558 | |
| 18 | Patterns of somatic structural variation in human cancer genomes Hit paper breakdown → | 2020 | 550 |
| 19 | 1996 | 490 | |
| 20 | Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing Hit paper breakdown → | 2020 | 476 |
About Malcolm J. Moore
Malcolm J. Moore is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Surgery and Pathology and Forensic Medicine, having authored 316 papers that have together received 57.6k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (72 papers), Colorectal Cancer Treatments and Studies (35 papers), Cancer Genomics and Diagnostics (31 papers), Testicular diseases and treatments (24 papers), Cancer Treatment and Pharmacology (16 papers), Bladder and Urothelial Cancer Treatments (16 papers), Genetic factors in colorectal cancer (13 papers) and Prostate Cancer Treatment and Research (12 papers). The work is most often cited by research in Oncology (29.6k citations), Cancer Research (11.8k citations), Pulmonary and Respiratory Medicine (9.7k citations), Hepatology (2.3k citations) and Pathology and Forensic Medicine (5.1k citations). Malcolm J. Moore has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Dongsheng Tu, Mace L. Rothenberg, Steven Gallinger, Russell K. Portenoy, Daniel D. Von Hoff, John Sahl Andersen, Anna Maria Storniolo, M. Christine Cripps, Peter G. Tarassoff and Derek J. Jonker. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research, Investigational New Drugs and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.